Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Wenzel, M; Koll, F; Hoeh, B; Humke, C; Siech, C; Mader, N; Sabet, A; Groener, D; Steuber, T; Graefen, M; Maurer, T; Brandts, C; Banek, S; Chun, FKH; Mandel, P.
Real-World Comparison of Cabazitaxel Versus ¹⁷⁷Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer.
J Nucl Med. 2025; 66(1): 61-66. Doi: 10.2967/jnumed.124.268807
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Koll Florestan Johannes
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: ¹⁷⁷Lu-vipivotide tetraxetan prostate-specific membrane antigen (¹⁷⁷Lu-PSMA) therapy is under current scientific investigation and aims to become established in the treatment of metastatic castration-resistant prostate cancer (mCRPC). However, real-world evidence in treatment comparison is scant. Methods: We relied on the FRAMCAP database and compared cabazitaxel versus ¹⁷⁷Lu-PSMA therapy in mCRPC patients regarding progression-free survival (PFS) and overall survival (OS). Sensitivity analyses addressed second- to fourth-line mCRPC treatment to approximate current phase III patient selection criteria. Results: Of 373 patients, 14% received cabazitaxel, 65% received ¹⁷⁷Lu-PSMA, and 21% received both. Patients undergoing ¹⁷⁷Lu-PSMA therapy were significantly older than cabazitaxel patients (median, 72 y vs. 66 y; P < 0.01), and a higher proportion had an Eastern Cooperative Oncology Group score of 2 or more (12% vs. 5.0%, P = 0.1). Rates of a prostate-specific antigen decline of at least 50% were 32% versus 0% for ¹⁷⁷Lu-PSMA versus cabazitaxel. In outcome analyses, significant superior median PFS was observed for ¹⁷⁷Lu-PSMA versus cabazitaxel (13.4 mo vs. 7.1 mo, P < 0.001), even after multivariable adjustment (hazard ratio, 0.38; P < 0.001). Regarding OS, rates also significantly differed, with median OS of 14.7 mo versus 16.5 mo versus 29.6 mo for cabazitaxel versus ¹⁷⁷Lu-PSMA versus both treatments (P < 0.01). In sensitivity analyses of second- to fourth-line mCRPC treatment, PFS rates and median OS rates for cabazitaxel versus ¹⁷⁷Lu-PSMA versus both therapies qualitatively remained the same as for the entire cohort. Conclusion: In a real-world setting, ¹⁷⁷Lu-PSMA provides significantly better PFS and qualitatively better OS rates than does cabazitaxel chemotherapy and should therefore be considered a valuable treatment option for advanced mCRPC patients according to the European Medicines Agency approval.
Find related publications in this database (using NLM MeSH Indexing): Humans - administration & dosage; Male - administration & dosage; Prostatic Neoplasms, Castration-Resistant - radiotherapy, pathology, drug therapy; Aged - administration & dosage; Lutetium - therapeutic use; Radiopharmaceuticals - therapeutic use; Taxoids - therapeutic use; Neoplasm Metastasis - administration & dosage; Middle Aged - administration & dosage; Dipeptides - therapeutic use; Aged, 80 and over - administration & dosage; Heterocyclic Compounds, 1-Ring - therapeutic use; Prostate-Specific Antigen - administration & dosage
Find related publications in this database (Keywords): mCRPC; PFS; OS; survival; 177 Lu